Health Care [ 6/12 ] | Biotechnology [ 43/73 ]
NASDAQ | Common Stock
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases.
Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration.
The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011.
Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 25 | -0.12 Increased by +40.00% | -0.19 Increased by +36.84% |
| May 13, 25 | -0.19 Decreased by -0.89% | -0.11 Decreased by -74.27% |
| Mar 27, 25 | -0.19 Decreased by -18.75% | -0.16 Decreased by -18.75% |
| Nov 11, 24 | -0.18 Increased by +25.00% | -0.20 Increased by +10.00% |
| Aug 13, 24 | -0.20 Decreased by -33.33% | -0.16 Decreased by -25.00% |
| May 15, 24 | -0.19 Increased by 0.00% | -0.16 Decreased by -18.75% |
| Mar 29, 24 | -0.16 Increased by +11.11% | -0.16 |
| Nov 13, 23 | -0.24 Decreased by -71.43% | -0.16 Decreased by -50.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -7.52 M Increased by +39.20% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -9.63 M Increased by +16.17% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 36.00 K Decreased by -55.00% | -11.97 M Decreased by -19.71% | Decreased by -33.24 K% Decreased by -166.01% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -11.22 M Decreased by -7.59% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -12.37 M Decreased by -35.74% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -11.49 M Increased by +0.33% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 80.00 K Increased by +N/A% | -10.00 M Increased by +5.99% | Decreased by -12.50 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.43 M Decreased by -21.30% | Decreased by N/A% Decreased by N/A% |